Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease

BACKGROUND: We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. METHODS: Retrospective review (May 2014–December 2016) of a prospectively maintained inflammatory bowel disease (IBD) registry. Kapl...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Inflamm Bowel Dis
Autori principali: Shmidt, Eugenia, Kochhar, Gursimran, Hartke, Justin, Chilukuri, Prianka, Meserve, Joseph, Chaudrey, Khadija, Koliani-Pace, Jenna L, Hirten, Robert, Faleck, David, Barocas, Morris, Luo, Michelle, Lasch, Karen, Boland, Brigid S, Singh, Siddharth, Vande Casteele, Niels, Sagi, Sashidhar Varma, Fischer, Monika, Chang, Shannon, Bohm, Matthew, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Hudesman, David, Gupta, Nitin, Kane, Sunanda, Loftus, Edward V, Sandborn, William J, Siegel, Corey A, Sands, Bruce E, Colombel, Jean-Frederic, Shen, Bo, Dulai, Parambir S
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2018
Soggetti:
Original Clinical Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693035/
https://ncbi.nlm.nih.gov/pubmed/29788240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izy171
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi